Ascentage Pharma Group International
SEC CIK 2023311 · AAPG · last insider filing 2026-06-29
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Yang Dajun | Director · Chairman and CEO | filed 2026 - 2026 |
| Lippman Marc E | Director | filed 2026 - 2026 |
| Sidransky David | Director | filed 2026 - 2026 |
| Bozilenko Marina | Director | filed 2026 - 2026 |
| Yu Debra | Director | filed 2026 - 2026 |
| Ye Changqing | Director | filed 2026 - 2026 |
| Lu Simon Dazhong | Director | filed 2026 - 2026 |
| Wang Shaomeng | Director | filed 2026 - 2026 |
| Wei Ren | Director | filed 2026 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Miyara Faical | Chief Business Officer | filed 2026 - 2026 |
| Zhai Yifan | Chief Medical Officer | filed 2026 - 2026 |
| Misra Veet | Chief Financial Officer | filed 2026 - 2026 |
| Cao Jin | Chief Accounting Officer | filed 2026 - 2026 |
| Knapp Thomas J c/o Sucampo Pharmaceuticals, Inc. | SVP/General Counsel | filed 2026 - 2026 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.